Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person! Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse. @RheumNow https://t.co/NiaUXzt4nT

• https://x.com/JihaRheum/status/1857486092846473222/photo/1

🔍 Safety of a JAKi Across 15,000 Patient-Years of Data Now in the RheumNow poster hall: Safety outcomes with a JAKi from 11 Phase 3 trials in adult patients with RA, PsA, AS, and nr-axSpA. Sponsored by AbbVie US Medical Affairs. https://t.co/yeif38wKIY https://t.co/earZnqZLSI

• Safety of a JAKi Across 15,000 Patient-Years of Data | RheumNow